Femasys Inc (FEMY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Femasys Inc stock (FEMY) is currently trading at $0.51. Femasys Inc PS ratio (Price-to-Sales) is 16.09. Analyst consensus price target for FEMY is $3.67. WallStSmart rates FEMY as Sell.
- FEMY PE ratio analysis and historical PE chart
- FEMY PS ratio (Price-to-Sales) history and trend
- FEMY intrinsic value — DCF, Graham Number, EPV models
- FEMY stock price prediction 2025 2026 2027 2028 2029 2030
- FEMY fair value vs current price
- FEMY insider transactions and insider buying
- Is FEMY undervalued or overvalued?
- Femasys Inc financial analysis — revenue, earnings, cash flow
- FEMY Piotroski F-Score and Altman Z-Score
- FEMY analyst price target and Smart Rating
Femasys Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Femasys Inc (FEMY) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Femasys Inc (FEMY) Key Strengths (1)
Revenue surging 31.40% year-over-year
Supporting Valuation Data
Femasys Inc (FEMY) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 16.1x annual revenue
Very expensive at 7.2x book value
Very low institutional interest at 10.59%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Femasys Inc (FEMY) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 31.40%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (16.09), Price/Book (7.22) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -376.20%, Operating Margin at -501.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -376.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 31.40% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FEMY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FEMY's Price-to-Sales ratio of 16.09x trades at a deep discount to its historical average of 88.28x (8th percentile). The current valuation is 97% below its historical high of 490.16x set in Jun 2021, and 24% above its historical low of 12.97x in Aug 2025. Over the past 12 months, the PS ratio has compressed from ~47.1x as trailing revenue scaled faster than the stock price.
Compare FEMY with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Femasys Inc (FEMY) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Femasys Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 2M with 31% growth year-over-year.
Key Findings
Revenue growing at 31% YoY, reaching 2M. This pace significantly outperforms most MEDICAL INSTRUMENTS & SUPPLIES peers.
Spending 67% of revenue (1M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Femasys Inc maintain 31%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Femasys Inc.
Bottom Line
Femasys Inc is a high-conviction growth story with revenue accelerating at 31% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(6 last 3 months)
| Insider | Type | Shares |
|---|---|---|
EICHENBAUM, KENNETH D. Director | Buy | +35,200 |
| Insider | Type | Shares |
|---|---|---|
SIPOS, JEREMY ALEXANDER Chief Technology Officer | Buy | +80,000 |
Data sourced from SEC Form 4 filings
Last updated: 11:32:40 AM
About Femasys Inc(FEMY)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Femasys Inc. is an innovative medical technology firm at the forefront of transforming women's healthcare through its proprietary solutions aimed at diagnosing and treating gynecological conditions. The company is particularly recognized for its flagship products that offer non-surgical alternatives for common issues such as uterine fibroids and contraception, positioning it as a leader in the evolving landscape of women's health. As demand for minimally invasive procedures grows, Femasys is strategically positioned to capitalize on this trend, enhancing patient outcomes while optimizing healthcare delivery. With a commitment to addressing significant unmet needs in women's health, Femasys aims to revolutionize the standards of care in this vital sector.